WSBTV Narconon GA Part 3 2012-10-03


 

WSBTV Narconon GA Part 3 2012-10-03 – WSB TV Action News Atlanta, GA investigative report of the tragic death of Patrick Desomond in 2008. Whistleblower, memo link Georgia Narconon to Scientology Channel 2 Investigation looks at nonprofit rehab program after patient death By Jodie Fleischer ATLANTA — A worldwide drug treatment program that’s denied its affiliation with the Church of Scientology faces new scrutiny now that a whistleblower has come forward. Channel 2 Action News has uncovered documents which tie Narconon of Georgia to the controversial church. Channel 2 investigative reporter Jodie Fleischer obtained records that show the director of the Georgia program knew staff members were drinking and doing drugs with patients. A whistleblower told Fleischer the program was more focused on its image than fixing problems and the church uses Narconon to make money and recruit vulnerable addicts into Scientology. Lucas Catton told Flesicher he knows the Narconon drug treatment program better than almost anyone. He went through it as a student, and then rose to be become president of the Flagship Arrowhead facility in Oklahoma. “Is it what it pretends to be? Absolutely not,” said Catton. “Narconon is, essentially it is Scientology.” read more and follow at: www.wsbtv.com

 

Alzheimer's: Are Antipsychotic Drugs Worth It?

Filed under: drug treatment news 2012

Oct. 17, 2012 — Extreme agitation, aggressiveness, and psychosis are common among people with Alzheimer's disease — especially in its later stages — and they are among the symptoms most often associated with admission to nursing homes. Antipsychotic …
Read more on WebMD

 

Drug Approval For PAH Treatment Could Send United Therapeutics To New Highs

Filed under: drug treatment news 2012

United Therapeutics (UTHR – Analyst Report) performed above expectations in the first half of 2012 and is positioned to continue performing well through the remainder of the year. This Zacks #1 Rank (Strong Buy) biotechnology company is well-positioned …
Read more on Forbes

 

Novel Anti-Inflammatory Drug Shows Promise for COPD

Filed under: drug treatment news 2012

CHF 6001, a new drug that targets inflammation in respiratory illnesses, has successfully completed its first phase of clinical trials showing promising results for the treatment of COPD and asthma. CHF 6001 is a PDE4 (phosphodiesterase 4) inhibitor, a …
Read more on About – News & Issues